This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s ...

In an era of increasing regulatory complexity, life sciences organizations are modernizing GxP compliance through digital ...

In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

In the fifth part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how ...

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and ...

This episode of Pharma Pulse examines how in-store pharmacies are evolving beyond prescriptions to deliver clinical services, ...

In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

In the final part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, outlines ...

In the fourth part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of supply chain operations & ...

Meanwhile, drugmakers ramp up U.S. manufacturing investments to navigate policy shifts and protect supply chain resilience.